Article

The first experimental study on a candidate combined vaccine against hepatitis A and hepatitis E.

Department of Microbiology and Immunology, School of Medicine, Southeast University, 87 Dingjiaqiao Road, Nanjing 210009, China.
Vaccine (Impact Factor: 3.49). 03/2007; 25(9):1662-8. DOI: 10.1016/j.vaccine.2006.11.001
Source: PubMed

ABSTRACT To test the possibility of developing a combined vaccine against hepatitis A and E, groups of mice were immunized with different formulations containing different dosages of a commercially inactivated hepatitis A vaccine and a candidate recombinant hepatitis E vaccine. Monovalent vaccine components were used as controls. The experimental results showed that the combined vaccine could induce neutralizing antibodies against both hepatitis A virus (HAV) and hepatitis E virus (HEV) effectively in mice. Moreover, the inactivated hepatitis A vaccine could increase the immunogenicity of the recombinant HEV protein, and the recombinant HEV protein had no adverse effects on the immunogenicity of the inactivated HAV vaccine. Thus, the present study demonstrates an important first step for the further development of a combined hepatitis A and E vaccine.

2 Followers
 · 
91 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Passive immunization is available against rabies, varicella, tetanus and hepatitis A and B. Active immunization is, in general, more efficacious with live attenuated viruses than with many of the bacterial vaccines. Toxoids, too, are very effective immunizing agents. Immunization usually starts at two months of age with DTP and oral poliovirus vaccine. For patients at high risk for secondary complications, influenza and pneumococcal immunizations are advisable. Hepatitis B vaccine is now available for persons at high risk because of their occupations.
    American family physician 03/1983; 27(2):249-53. · 1.82 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Les virus de l’hépatite A (VHA) et de l’hépatite E (VHE) sont des virus à ARN non enveloppés. Ils sont responsables d’hépatites aiguës caractérisées par une absence de progression vers la forme chronique et l’absence de portage prolongé. C’est la raison pour laquelle, afin d’assurer la survie de l’espèce, ces deux virus utilisent un mode de transmission particulièrement efficace : la voie féco-orale. Malgré ce point commun, il existe des différences importantes entre ces deux agents infectieux au niveau de leurs caractères virologiques, de leur épidémiologie et des moyens disponibles pour la prophylaxie. Le VHA est un membre de la famille des Picornaviridae, alors que le VHE appartient à la petite famille des Hepeviridae. Bien que plusieurs génotypes soient identifiés pour ces deux virus, il n’existe qu’un seul sérotype pour chacun. l’homme est l’unique réservoir du VHA. Sa transmission est liée aux mauvaises conditions d’hygiène. La progression du niveau socio-économique ainsi que l’amélioration de l’hygiène standard ont réduit la transmission du VHA dans les pays développés. l’âge moyen d’exposition au virus a augmenté, conduisant à l’apparition d’une partie de la population des adolescents et des adultes sensible à l’infection. Au contraire du VHA, le VHE est une zoonose. Le virus est retrouvé dans les selles d’un grand nombre d’espèces animales. Le porc semble cependant le réservoir majeur. l’hépatite E survient essentiellement, dans les pays en développement, responsable d’épidémies d’origine hydrique de grande ampleur. La transmission interhumaine est moins fréquente que pour le VHA. Dans les pays développés, la plupart des cas sont considérés comme importés. Cependant, durant ces dernières années, de plus en plus de cas sporadiques d’origine autochtone sont rapportés. Le taux de séroprévalence est de 1 à 5%. Cela tend à démontrer que la prévalence du VHE serait plus importante que prévue dans les pays industrialisés. l’immunisation grâce au vaccin inactivé contre le VHA conduit à une immunité très efficace, rapide et de longue durée. Les modifications du profil épidémiologique des infections par le VHA dans de nombreux pays devraient conduire à une r évision des politiques vaccinales. Quelques vaccins contre le VHE font actuellement l’objet d’essais cliniques. Hepatitis A virus (HAV) and hepatitis B virus (HBV) are two non-enveloped RNA viruses, which cause acute hepatitis with no progression to chronic liver disease and no chronic carriage. This is why, for their survival, these two viruses have a particularly efficient transmission mechanism: the faecal-oral route. Despite this similarity, there are significant differences between HAV and HEV with respect to their viral characteristics, their epidemiology and their treatment. HAV is a member of the Picornaviridae, while HEV belongs to the small Hepeviridae family. Although several genotypes have been identified for these two viruses, only one serotype is recognized for each. For HAV, humans are the only reservoir. The infection is associated with poor sanitation. Socioeconomic improvements and better hygiene standards have reduced the transmission of HAV in developed countries. The mean age of exposure has increased, resulting in large numbers of teenagers and adults becoming susceptible to the virus. Unlike HAV, HEV is zoonotic. The virus is found in the faeces of many animals although pigs seem to be the main reservoir. Hepatitis E occurs predominantly in developing countries, resulting in large water-born epidemics. Person-to-person transmission is less frequent. In developed countries, most HEV infections are thought to be imported. In the last few years, increasing numbers of sporadic cases have been described in indigenous patients, while the seroprevalence ranges from 1 to 5%. This suggests that HEV may be more prevalent than previously considered in industrialized countries. Immunization with inactivated HAV vaccine results in highly effective, rapid and long-lasting immunity. The changing epidemiology of HAV infections in many countries should lead to a review of vaccination strategies. Several vaccines against HEV are currently undergoing evaluation in clinical trials.
    Journal Africain d?Hépato-Gastroentérologie 01/2007; 1(3):115-122. DOI:10.1007/s12157-008-0027-z
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although the development and licensure of new vaccines over the last 2 years has generated a lot of excitement as well as debate, there is a lot more to come. Not discussed in this article. licensure of another long-awaited vaccine albeit for use in adults was that for herpes zoster. The second HPV and rotavirus vaccines are awaiting approval in the US. Next in line are the vaccines both prophylactic as well as therapeutic against HIV. Topics of debate over the new vaccines include discussions amongst practices as to the affordability and cost of the new vaccines as well as the ethical debate amongst lawmakers and the general public regarding the rights and wrongs of compulsory vaccination against HPV. Another ongoing discussion is regarding the availability of approved vaccines. Shortages have been seen with several of the childhood vaccines including heptavalent pneumococcal conjugate vaccine, tetravalent meningococcal conjugate vaccine, hepatitis A vaccine, as well as the ongoing saga with influenza vaccines. Across the globe while the struggle against polio continues, there is encouraging news regarding the reduction in measles-related deaths, particularly in Africa. The last few years have indeed been landmark years in infectious disease research as the search continues for better and safer vaccines globally.
    Advances in Pediatrics 02/2007; 54(1):135-71. DOI:10.1016/j.yapd.2007.03.009
Show more